Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects, best dose, and effectiveness of copanlisib
and venetoclax in treating patients with mantle cell lymphoma that has come back (relapsed)
or does not respond to treatment (refractory). Copanlisib may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth. Venetoclax may stop the growth of
cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving copanlisib
and venetoclax may help treat patients with mantle cell lymphoma.